April 27, 2009 — The US Food and Drug Administration (FDA) has approved golimumab (Simponi, Centocor Ortho Biotech Inc) for monthly subcutaneous injection in the treatment of adults with ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis BOSTON, Nov. 7 -- Patients with active psoriatic ...

PARIS, June 11 -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX) ...

November 24, 2009 (San Diego, California) — A new fully human monoclonal antibody (MAb) against TNF, golimumab (CNTO148, Centocor/Schering-Plough), is close to entering the market. Results from a ...

SAN DIEGO, CA—The final 5-year results from the GO-FORWARD trial showed a high retention rate and improvements in signs/symptoms of rheumatoid arthritis (RA) and in physical function were maintained ...

June 12 -- WEDNESDAY, June 11 (HealthDay News) -- Adding monthly injections of golimumab to weekly doses of methotrexate helped most people with rheumatoid arthritis, even putting some into remission, ...

SAN DIEGO, CA—Golimumab plus methotrexate maintains improvements in signs and symptoms of rheumatoid arthritis and physical function and inhibits structural damage progression long-term, according to ...

Johnson & Johnson and Schering-Plough have posted some very promising data from three late-stage rheumatoid arthritis trials of their investigational anti-tumour necrosis factor therapy golimumab.

Golimumab (Simponi, Schering-Plough/Centocor) is a human monoclonal antibody that prevents the binding of tumour necrosis factor (TNF) to its receptors, thereby neutralising its activity. Golimumab ...

PARIS, France - 11 June 2008 – Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly ...

PARIS, June 11 Findings from two new Phase 3 studiesshowed that patients receiving every four-week subcutaneous injections ofgolimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate ...